Enthera Pharmaceuticals

We are excited to participate in the 19th Congress of the European Crohn´s and Colitis Organization - ECCO'24 (ecco-ibd.eu) conference on February 21st-24th in Stockholm.   Enthera Pharmaceuticals will be presenting new data demonstrating the therapeutic activity of our first-in-class anti-TMEM219 monoclonal antibody, Ent001, on mucosal healing (Abstract #EC24-1569).  Come and check out our poster entitled "Rescuing Intestinal Stem Cells via TMEM219 inhibition promotes mucosal healing in Crohn’s disease" during the guided poster session on Friday February 23rd from 12:40 - 13:40, presentation number “P171”. #Enthera #IBD #crohnsdisease #ulcerativecolitis #chronicdisease #crohnsandcolitis #colitis #ECCO2024 #ECCO24 #inflammatoryboweldisease

We are thrilled to welcome Lisa Olson, Ph.D., as Enthera’s CEO as she moves from our Board to the management team. Lisa is a seasoned industry veteran, and we look forward to benefiting from her two decades of leadership experience cultivated across the pharmaceutical and biotechnology industries. She takes the helm as we initiate enrollment for a new Phase 1b trial with our lead candidate, Ent001 in patients with ulcerative colitis after having completed a Phase 1a study in healthy volunteers with positive safety and tolerability results. For more details on Lisa’s appointment and updates on our clinical trial progress with Ent001, read the press release at: https://lnkd.in/deAFJBYG #monoclonalantibody #phase1 #ulcerativecolitis #inflammatoryboweldisease

We are thrilled to welcome Lisa Olson, Ph.D., as Enthera’s CEO as she moves from our Board to the management team. Lisa is a seasoned industry veteran, and we look forward to benefiting from her two decades of leadership experience cultivated across the pharmaceutical and biotechnology industries. She takes the helm as we initiate enrollment for a new Phase 1b trial with our lead candidate, Ent001 in patients with ulcerative colitis after having completed a Phase 1a study in healthy volunteers with positive safety and tolerability results. For more details on Lisa’s appointment and updates on our clinical trial progress with Ent001, read the press release at: https://lnkd.in/deAFJBYG #monoclonalantibody #phase1 #ulcerativecolitis #inflammatoryboweldisease